RXSTNasdaqOphthalmic GoodsFiscal year ends December 31
RxSight, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.69+0.18 (+3.99%)
Close on Oct 19, 2026
- Market cap
- $194.59M
- P/E (TTM)
- –
- Dividend yield
- –
RxSight, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $27.24M | – | – | – | $33.64M | – | – | – | – | – | – | – | 80.7% | -19.0% |
| LAL | $24.50M | $27.04M | $28.18M | $25.69M | $27.01M | $27.19M | $28.52M | $24.23M | $23.83M | $19.92M | $17.78M | $13.50M | 72.6% | -9.3% |
| License and collaboration revenue | $6.50M | – | – | – | $0 | – | – | – | – | – | – | – | 19.3% | – |
| Service Warranty Service Contracts And Accessories | $1.40M | $1.51M | $1.46M | $1.47M | $1.50M | $1.32M | $1.02M | $955.00K | $870.00K | $882.00K | $832.00K | $765.00K | 4.2% | -6.3% |
| L D D | $1.34M | $2.35M | $2.97M | $3.17M | $5.13M | $9.39M | $10.67M | $10.13M | $10.19M | $8.71M | $9.96M | $7.93M | 4.0% | -73.9% |
By region
From the segment and revenue-disaggregation notes of RxSight's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.